Meeting
2022 ASCO Annual Meeting
A phase 1 adoptive cell therapy using drug-enhanced, tumor-infiltrating lymphocytes, DeTIL-0255, in adults with advanced malignancies.
Authors
Eugenia Girda
Rutgers Cancer Inst of New Jersey, New Brunswick, NJ
Eugenia Girda , Emese Zsiros , John Nakayama , Sarah Whelan , Srinand Nandakumar , Seema Rogers , Beverly Benson , Frank G. Basile , Michael T. Lotze , Robert James Brown , Robert Michael Wenham
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Cervical Cancer
Clinical Trial Registration Number
NCT05107739
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS5602)
DOI
10.1200/JCO.2022.40.16_suppl.TPS5602
Abstract #
TPS5602
Poster Bd #
477b
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
IOV-3001, a modified interleukin-2 fusion protein, for potential use in tumor-infiltrating lymphocyte cell therapy regimens.
First Author: Michelle R. Abelson
Poster
2023 ASCO Annual Meeting
Phase I study of MP0317, a FAP-dependent DARPin, for tumor-localized CD40 activation in patients with advanced solid tumors.
First Author: Carlos A. Gomez-Roca
Poster
2023 ASCO Annual Meeting
A phase 3 study (TILVANCE-301) to assess the efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, in combination with pembrolizumab compared with pembrolizumab alone in patients with untreated unresectable or metastatic melanoma.
First Author: Daniel Olson
Poster
2022 ASCO Annual Meeting
First-in-human clinical trial of an oncolytic adenovirus armed with TNFa and IL-2 in patients with advanced melanoma receiving adoptive cell transfer of tumor-infiltrating lymphocytes.
First Author: Inge Marie Svane